david harter
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF , RAF , or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR , and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.
Year:
2024
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF , RAF , or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR , and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.
Year:
2024
Collaborators (9)
Matija Snuderl
Assistant Professor (Clinical) of Pathology
NYU School of Medicine
George Jour
Associate professor
NYU Langone Medical Center
Jeffrey Wisoff
Professor of Neurosurgery and Pediatrics
NYU School of Medicine
Tejus Bale
Assistant Attending L1
Memorial Sloan Kettering Cancer Center
Eveline Teresa Hidalgo
NYU Langone Health
Jeffrey Allen
Otto and Marguerite Manley and Making Headway Foundation Professor of Pediatric Neuro-Oncology and Professor (Clinical) of Neurology
NYU School of Medicine
Daniel Orringer
Associate Professor
NYU Langone Health
Benjamin Liechty
Assistant Professor of Pathology and Laboratory Medicine
Weill Cornell Medicine
Sharon L Gardner
Associate Professor (Clinical) of Pediatrics
NYU School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.